Science & Systems6 h ago
Daraxonrasib shrinks pancreatic tumours, with some becoming undetectable
In a trial of 61 patients, daraxonrasib stopped or shrunk tumours in almost all.
Reported by The Guardian
ShareWhy it matters
Pancreatic cancer currently kills half of patients within three months; this could extend life for people facing one of the deadliest cancers.
In Australia. If approved for use, daraxonrasib could offer hope to Australian patients with advanced pancreatic cancer, which has very poor survival rates.
Key facts
- 61 patients
- Trial size
- 90%
- Tumours stopped growing
- 76.6%
- One-year survival on daraxonrasib
- 40-45%
- One-year survival on chemotherapy alone






